Toxoplasma gondii: Fluconazole and itraconazole activity against toxoplasmosis in a murine model

Experimental Parasitology

Volumn 124, Issue 4, 2010, Pages 466-469

  Martins Duarte, Érica S ^a   Lemgruber, Leandro ^a   de Souza, Wanderley ^a,b   Vommaro, Rossiane C ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Diretoria de Programas   (Brazil)

Author keywords

Apicomplexa; Azole; Chemotherapy; Toxoplasma gondii

Indexed keywords

DIFFUCAP; FLUCONAZOLE; ITRACONAZOLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CYST; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; DRUG SELECTIVITY; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TOXICITY TESTING; TOXOPLASMA GONDII; TOXOPLASMOSIS;

APICOMPLEXA; MURINAE; MUS; TOXOPLASMA GONDII;

EID: 76849113239     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2009.12.011     Document Type: Article

References (24)

1. Cornelissen A.W., Overdulve J.P., Hoenderboom J.M. Separation of Isospora (Toxoplasma) gondii cysts and cystozoites from mouse brain tissue by continuous density-gradient centrifugation. Parasitology 1981, 83:103-108.
2. Djurković-Djaković O., Milenković V., Nikolić A., Bobić B., Grujić J. Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii. Journal of Antimicrobial Chemotherapy 2002, 50:981-987.
3. Djurković-Djaković O., Nikolić A., Bobić B., Klun I., Aleksić A. Stage conversion of Toxoplasma gondii RH parasites in mice by treatment with atovaquone and pyrrolidine dithiocarbamate. Microbes and Infection 2005, 7:49-54.
4. Dubey J.P. Advances in the life cycle of Toxoplasma gondii. International Journal of Parasitology 1998, 28:1019-1024.
5. Ferguson D.J., Huskinson-Mark J., Araujo F.G., Remington J.S. An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii. International Journal of Experimental Pathology 1994, 75:111-116.
6. Ferreira-da-Silva Mda.F., Barbosa H.S., Gross U., Lüder C.G. Stress-related and spontaneous stage differentiation of Toxoplasma gondii. Molecular BioSystems 2008, 4:824-834.
7. Girois S.B., Chapuis F., Decullier E., Revol B.G.P. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. European Journal of Clinical Microbiology & Infectious Diseases 2005, 24:119-130.
8. Goa K.L., Barradell L.B. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995, 50:658-690.
9. Grant S.M., Clissold S.P. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989, 37:310-344.
10. Gross U., Pohl F. Influence of antimicrobial agents on replication and stage conversion of Toxoplasma gondii. Current Topics in Microbiology and Immunology 1996, 219:235-245.
11. Haverkos H.W. Assessment of therapy for toxoplasma encephalitis. The TE Study Group. The American Journal of Medicine 1987, 82:907-914.
12. Howe D.K., Sibley L.D. Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease. Journal of Infectious Disease 1995, 172:1561-1566.
13. Luft B.J., Hafner R., Korzum A.H., Leport C., Antoniskis D., Bosler E.M., et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. The New England Journal of Medicine 1993, 329:995-1000.
14. Luft B.J., Remington J.S. Toxoplasmic encephalitis in AIDS. Clinical Infectious Diseases 1992, 15:211-222.
15. Martins-Duarte Edos.S., de Souza W., Vommaro R.C. Itraconazole affects Toxoplasma gondii endodyogeny. FEMS Microbiology Letters 2008, 282:290-298.
16. Montoya J.G., Liesenfeld O. Toxoplasmosis. Lancet 2004, 363:1965-1976.
17. Mordue D.G., Monroy F., La Regina M., Dinarello C.A., Sibley L.D. Acute toxoplasmosis leads to lethal overproduction of Th1 cytokines. Journal of Immunology 2001, 167:4574-4584.
18. Nobre V., Braga E., Rayes A., Serufo J.C., Godoy P., Nunes N., Antunes C.M., Lambertucci J.R. Opportunistic infections in patients with AIDS admitted to an university hospital of the Southeast of Brazil. Revista do Instituto de Medicina Tropical de São Paulo 2003, 45:69-74.
19. Nwaka S., Hudson A. Innovative lead discovery strategies for tropical diseases. Nature Reviews. Drug Discovery 2006, 5:941-955.
20. Pfefferkorn E.R., Pfefferkorn L.C. Specific labeling of intracellular Toxoplasma gondii with uracil. The Journal of Protozoology 1977, 24:449-453.
21. Sheehan D.J., Hitchcock C.A., Sibley C.M. Current and emerging azole antifungal agents. Clinical Microbiology Reviews 1999, 12:40-79.
22. Swisher C.N., Boyer K., McLeod R. Congenital toxoplasmosis. The Toxoplasmosis Study Group. Seminars in Pediatric Neurology 1994, 1:4-25.
23. Tenter A.M., Heckeroth A.R., Weiss L.M. Toxoplasma gondii: from animals to humans. International Journal for Parasitology 2000, 30:1217-1258.
24. Tomavo S., Boothroyd J.C. Interconnection between organellar functions, development and drug resistance in the protozoan parasite, Toxoplasma gondii. International Journal for Parasitology 1995, 25:1293-1299.